Monte Rosa Therapeutics (GLUE) Assets Average (2021 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Assets Average of $592.5 million for Q1 2026, up 42.45% year-over-year from $416.0 million in Q1 2025, and up 30.44% quarter-over-quarter from $454.2 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Assets Average (2021 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $592.5 million for Q1 2026.
- In Q1 2026, Assets Average rose 42.45% year-over-year to $592.5 million; the TTM figure through Mar 2026 stood at $592.5 million (up 42.45% YoY), while the FY2025 annual figure was $443.7 million, up 19.52% from the prior year.
- Assets Average for Q1 2026 stood at $592.5 million, up from $454.2 million in the prior quarter.
- The five-year high for Assets Average was $592.5 million in Q1 2026, with the low at $265.4 million in Q3 2023.
- The 5-year median for Assets Average is $355.5 million (2022), against an average of $360.7 million.
- The sharpest annual moves came in 2023 and 2025: Assets Average decreased 26.56% in 2023, then jumped 45.82% in 2025.
- Monte Rosa Therapeutics' Assets Average stood at $350.0 million in 2022, then dropped by 20.59% to $277.9 million in 2023, then soared by 35.61% to $376.9 million in 2024, then gained by 20.52% to $454.2 million in 2025, then soared by 30.44% to $592.5 million in 2026.
- Business Quant data shows GLUE's Assets Average at $592.5 million in Q1 2026, $454.2 million in Q4 2025, and $409.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 713.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 713.79 Mn |
| Mar 31, 2026 | 592.54 Mn |
| Dec 31, 2025 | 454.25 Mn |
| Sep 30, 2025 | 409.71 Mn |
| Jun 30, 2025 | 376.39 Mn |
| Mar 31, 2025 | 415.97 Mn |
| Dec 31, 2024 | 376.91 Mn |
| Sep 30, 2024 | 329.60 Mn |
| Jun 30, 2024 | 305.43 Mn |
| Mar 31, 2024 | 285.25 Mn |
| Dec 31, 2023 | 277.93 Mn |
| Sep 30, 2023 | 265.36 Mn |
| Jun 30, 2023 | 293.82 Mn |
| Mar 31, 2023 | 325.71 Mn |
| Dec 31, 2022 | 350.00 Mn |
| Sep 30, 2022 | 361.33 Mn |
| Jun 30, 2022 | 355.53 Mn |
| Mar 31, 2022 | 356.17 Mn |
| Dec 31, 2021 | 375.19 Mn |
| Sep 30, 2021 | 376.50 Mn |